Geneva, Aug. 29 -- International Clinical Trials Registry received information related to the study (NCT07133763) titled 'Application of PD-1 Inhibitors, Tenofovir, Chidamide, and Lenalidomide in Relapsed/Refractory EBV-associated Lymphoproliferative Disorders' on Aug. 4.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: The Affiliated Hospital of Xuzhou Medical University
Condition:
EBV-Associated Lymphoproliferative Disorders
PD-1 Inhibitor
Tenofovir
Chidamide
Lenalidomide
Intervention:
Drug: PD-1 Inhibitor Combined with Tenofovir, Chidamide, and Lenalidomide for the Treatment of EBV-Associated Lymphoprol...